Yin Yang

发表

A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas.

R. Advani, J. Winter, Y. Oki, 2013, Clinical advances in hematology & oncology : H&O.

Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2013 .

Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

S. de Vos, D. Maloney, I. Yakoub-Agha, 2021, Blood.

Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update

R. Advani, J. Connors, T. Illidge, 2011 .

Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

G. Salles, D. Maloney, V. Plaks, 2020 .

Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2010 .

Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)

P. Riedell, F. Milletti, J. Kawashima, 2020, Blood.

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

M. Kersten, P. Riedell, L. Gordon, 2021, The New England journal of medicine.

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.

G. Salles, S. de Vos, D. Maloney, 2021, The Lancet. Oncology.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

R. Advani, J. Connors, T. Illidge, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24).

G. Salles, D. Maloney, V. Plaks, 2021 .

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

M. Kersten, P. Riedell, L. Gordon, 2021, Blood.

Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5

G. Salles, D. Maloney, V. Plaks, 2020 .

A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.

Myung Ah Lee, P. Philip, A. Hezel, 2018 .

The Aethera Trial: An Ongoing Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant

P. Stiff, T. Masszi, J. Walewski, 2014 .

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

M. Kersten, P. Riedell, L. Gordon, 2021, New England Journal of Medicine.

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.

M. Kersten, P. Riedell, D. Miklos, 2023, The New England journal of medicine.

IBCL-124: Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL)

G. Salles, D. Maloney, V. Plaks, 2020 .

Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.

R. Advani, J. Connors, T. Illidge, 2012 .